Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2018 Filed Aug 23, 2018 20:36 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Exercise / conversionOrdinary Shares | 23,175 | $43.15 | $1,000,001.25 |
DisclosureSEC source: 0001127602-18-026096 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 16:42 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Tax withholdingOrdinary Shares | 2,806 | $90.48 | $253,886.88 |
DisclosureSEC source: 0001127602-18-024854 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,074 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 16:40 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 4,156 | $90.48 | $376,034.88 |
DisclosureSEC source: 0001127602-18-024851 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,499 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:29 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Tax withholdingOrdinary Shares | 7,585 | $90.48 | $686,290.80 |
DisclosureSEC source: 0001127602-18-024843 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,505 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:34 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
Tax withholdingOrdinary Shares | 4,987 | $90.48 | $451,223.76 |
DisclosureSEC source: 0001127602-18-024847 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,352 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:32 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
Tax withholdingOrdinary Shares | 27,010 | $90.48 | $2,443,864.80 |
DisclosureSEC source: 0001127602-18-024845 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,816 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:37 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Tax withholdingOrdinary Shares | 5,818 | $90.48 | $526,412.64 |
DisclosureSEC source: 0001127602-18-024849 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,653 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:38 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
Tax withholdingOrdinary Shares | 4,780 | $90.48 | $432,494.40 |
DisclosureSEC source: 0001127602-18-024850 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,202 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 16:41 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Tax withholdingOrdinary Shares | 3,954 | $90.48 | $357,757.92 |
DisclosureSEC source: 0001127602-18-024853 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,108 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 16:30 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 4,822 | $90.48 | $436,294.56 |
DisclosureSEC source: 0001127602-18-024844 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,647 Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 17:12 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Tax withholdingOrdinary Shares | 207 | $90.24 | $18,679.68 |
DisclosureSEC source: 0001127602-18-024470 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,879 Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:08 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024253 · form4.xml · derivative · entry 3 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:08 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 63,263 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024253 · form4.xml · derivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,263 Underlying: Ordinary Shares · 63,263 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:08 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantOrdinary Shares | 10,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024253 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,086 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 718 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:04 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024248 · form4.xml · derivative · entry 5 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:04 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 49,707 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024248 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,707 Underlying: Ordinary Shares · 49,707 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:04 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantOrdinary Shares | 8,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024248 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,654 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 211 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:44 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024238 · form4.xml · derivative · entry 5 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:44 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 99,414 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024238 · form4.xml · derivative · entry 4 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,414 Underlying: Ordinary Shares · 99,414 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:44 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantOrdinary Shares | 16,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024238 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,089 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 2155 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 61,004 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,004 Underlying: Ordinary Shares · 61,004 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantOrdinary Shares | 10,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,339 F1 · security: This balance increased by 312 shares due to exempt transactions such as dividend reinvestment. F2 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:48 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantStock Option (Right to Buy) · Derivative | 305,018 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024241 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,018 Underlying: Ordinary Shares · 305,018 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:48 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantOrdinary Shares | 50,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024241 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,826 F1 · security: This balance increased by 10,213 shares due to exempt transactions such as dividend reinvestment. F2 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 20:03 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024247 · form4.xml · derivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 20:03 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 85,067 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024247 · form4.xml · derivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,067 Underlying: Ordinary Shares · 85,067 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 20:03 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 14,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024247 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,371 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 243 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:51 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024243 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:51 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 67,782 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024243 · form4.xml · derivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,782 Underlying: Ordinary Shares · 67,782 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:51 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantOrdinary Shares | 11,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024243 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,471 F1 · security: This balance increased by 403 shares due to exempt transactions such as dividend reinvestment. F2 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:54 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024244 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:54 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 67,782 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024244 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,782 Underlying: Ordinary Shares · 67,782 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:54 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantOrdinary Shares | 11,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024244 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,981 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 924 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:06 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024251 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:06 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 58,745 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024251 · form4.xml · derivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,745 Underlying: Ordinary Shares · 58,745 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:06 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 9,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024251 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,062 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 906 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 56,485 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,485 Underlying: Ordinary Shares · 56,485 shares Expires 2028-07-30 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantOrdinary Shares | 9,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,472 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2018 Filed Jul 31, 2018 15:17 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 10,038 | $88.66 | $889,969.08 |
DisclosureSEC source: 0001127602-18-024106 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,117 F1 · balance_after: This balance increased by 1,327 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2018 Filed Aug 2, 2018 17:22 UTC Amendment |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 9,042 | $88.66 | $801,663.72 |
DisclosureSEC source: 0001127602-18-024486 · form4a.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,113 F1 · shares: Too many tax shares were initially withheld in error. This has been corrected from 10038 to 9042. Read SEC document |
| June 22, 2018 Filed Jul 6, 2018 16:41 UTC |
Surface Carol ASVP, Chief HR Officer
|
OtherOrdinary Shares | 265 | $86.81 | $23,004.65 |
DisclosureSEC source: 0001127602-18-022929 · form4.xml · nonDerivative · entry 2 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Indirect · NQ Ret Plan Sup Disclosed balance after: 532 F1 · security: This balance was previously incorrectly included in the 401(k) balance. Read SEC document |
| June 22, 2018 Filed Jul 6, 2018 16:41 UTC |
Surface Carol ASVP, Chief HR Officer
|
OtherOrdinary Shares | 720 | $86.81 | $62,503.20 |
DisclosureSEC source: 0001127602-18-022929 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 1,560 Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:49 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Tax withholdingOrdinary Shares | 6,527 | $86.13 | $562,170.51 |
DisclosureSEC source: 0001127602-18-021696 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,039 F1 · balance_after: This balance increased by 1,036 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 16:37 UTC |
POZEN ROBERT CDirector
|
GiftOrdinary Shares | 11,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020796 · form4.xml · nonDerivative · entry 1 POZEN ROBERT C · CIK 0001278408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,543 Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:35 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 8,910 | $86.82 | $773,566.20 |
DisclosureSEC source: 0001127602-18-020693 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,842 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.82 to $86.8202, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This balance increased by 792 shares due to exempt transactons such as dividend reinvestment. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:36 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
SaleOrdinary Shares | 11,500 | $87.13 | $1,001,995.00 |
DisclosureSEC source: 0001127602-18-020614 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,923 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $87.09 to $87.155, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4. F2 · balance_after: This balance increased by 316 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 01, 2018 Filed May 2, 2018 15:04 UTC |
OLEARY DENISE MDirector
|
Tax withholdingOrdinary Shares | 616 | $81.01 | $49,902.16 |
DisclosureSEC source: 0001127602-18-015922 · form4.xml · nonDerivative · entry 2 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,266 Read SEC document |
| May 01, 2018 Filed May 2, 2018 18:59 UTC |
JACKSON SHIRLEY ADirector
|
Tax withholdingOrdinary Shares | 616 | $81.01 | $49,902.16 |
DisclosureSEC source: 0001127602-18-015915 · form4.xml · nonDerivative · entry 2 JACKSON SHIRLEY A · CIK 0001168019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,525 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.